Cite
Efficacy of nivolumab as second line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a national DAHANCA cohort study
MLA
Sebastian Søby, et al. “Efficacy of Nivolumab as Second Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A National DAHANCA Cohort Study.” Acta Oncologica (Stockholm, Sweden), vol. 61, no. 8, Aug. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a6223af21be2cc40e5ee4aef8d457eea&authtype=sso&custid=ns315887.
APA
Sebastian Søby, Anita Gothelf, Niels Gyldenkerne, Jens Bentzen, Kinga Nowicka-Matus, Trine Tramm, & Jesper Grau Eriksen. (2022). Efficacy of nivolumab as second line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a national DAHANCA cohort study. Acta Oncologica (Stockholm, Sweden), 61(8).
Chicago
Sebastian Søby, Anita Gothelf, Niels Gyldenkerne, Jens Bentzen, Kinga Nowicka-Matus, Trine Tramm, and Jesper Grau Eriksen. 2022. “Efficacy of Nivolumab as Second Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A National DAHANCA Cohort Study.” Acta Oncologica (Stockholm, Sweden) 61 (8). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a6223af21be2cc40e5ee4aef8d457eea&authtype=sso&custid=ns315887.